Estrella Immunopharma
ESLA
7 hedge funds and large institutions have $129K invested in Estrella Immunopharma in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
0.03% less ownership
Funds ownership: 0.37% → 0.34% (-0.03%)
22% less capital invested
Capital invested by funds: $166K → $129K (-$36.3K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.74K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.62K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$80 |
| 4 |
JP Morgan Chase
New York
|
+$27 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HHGC
Hunting Hill Global Capital
New York
|
-$26.5K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$92 |
ESLA Hedge Fund Activity: Q2 2024 in Review
7 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q2 2024, worth a combined $129K — down 22% from $166K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ESLA positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $7.74K. The largest seller was Hunting Hill Global Capital, exiting entirely with an estimated $26.5K sold.
- 7 institutional investors held Estrella Immunopharma (ESLA) as of Q2 2024, up from 6 in Q1 2024.
- Funds reported $129K of Estrella Immunopharma stock for Q2 2024, down 22% quarter-over-quarter.
- 3 funds opened new Estrella Immunopharma positions in Q2 2024 and 2 closed out, a net change of +1 holder.
- The largest Estrella Immunopharma buyer in Q2 2024 was BlackRock, an estimated $7.74K added.
- The largest Estrella Immunopharma seller in Q2 2024 was Hunting Hill Global Capital, an estimated $26.5K sold.
Based on aggregated 13F filings for Q2 2024.